Voltage-dependent calcium channel (VDCC) (VDCC)

Voltage-dependent calcium channels (VDCCs) are a group of transmembrane proteins that facilitate the entry of calcium ions (Ca2+) into excitable cells, such as neurons, cardiomyocytes, and muscle fibers, in response to membrane depolarization (Catterall, 2011, Cold Spring Harb Perspect Biol). These channels are essential for coupling electrical excitation to intracellular signaling, thereby regulating processes such as muscle contraction, neurotransmitter release, and gene expression (UniProt, 2024). Structurally, VDCCs are heteromultimeric complexes composed of a pore-forming alpha-1 subunit and several auxiliary subunits, including alpha-2-delta, beta, and sometimes gamma, which modulate the channel's biophysical properties and trafficking (Zamponi et al., 2015, Pharmacol Rev). They are classified into high-voltage-activated (L-, P/Q-, N-, and R-type) and low-voltage-activated (T-type) channels based on their activation thresholds and pharmacological sensitivities (StatPearls, 2023). VDCCs are significant therapeutic targets; for instance, L-type channels are targeted by dihydropyridines for hypertension, while N-type channels and alpha-2-delta subunits are targeted for chronic pain management (PubMed, 2023). Dysregulation of these channels is implicated in a wide range of pathologies, including cardiovascular diseases, epilepsy, and chronic pain syndromes (PubChem, 2024).

Other names

Voltage-gated calcium channelVGCCCalcium channel, voltage-dependentVoltage-dependent calcium channels

Drugs targeting VDCCs primarily act as inhibitors or modulators of calcium ion conductance. L-type calcium channel blockers (e.g., amlodipine, verapamil) bind to the alpha-1 subunit to stabilize the inactivated state, thereby reducing calcium influx into vascular and cardiac cells (StatPearls, 2023). Gabapentinoids (e.g., gabapentin, pregabalin) bind to the alpha-2-delta auxiliary subunit, which inhibits the trafficking of the channel complex to the cell surface and reduces excitatory neurotransmitter release (Zamponi et al., 2015, Pharmacol Rev). Ziconotide acts as a selective, direct pore blocker of N-type (Cav2.2) channels to inhibit nociceptive signaling in the spinal cord (PubChem, 2024).